ABBV
AbbVie Inc.
NYSEUSDEQUITY
DELAYED
Last price
266.17
▲ 4.34 (1.66%)
MARKET · —
Price
Open
261.79
Prev close
261.83
Day high
266.83
Day low
260.10
Volume
5.14M
Market cap
—
P/E (TTM)
—
52W range
190.75 – 267.47
Trailing performance
Returnvs SPY
1W
+6.21%
+7.6%
1M
+3.13%
-0.6%
3M
+23.52%
+20.4%
6M
+17.86%
+6.8%
YTD
+15.96%
+3.7%
1Y
+26.68%
+6.7%
3Y
+74.83%
+0.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
254.91
+4.42% from price
SMA 20
253.29
+4.61% from price
SMA 50
247.99
+6.84% from price
SMA 100
229.20
+16.13% from price
SMA 200
226.56
+16.95% from price
EMA 12
256.28
+3.86% from price
EMA 26
252.74
+5.32% from price
EMA 50
246.52
+7.97% from price
RSI (14)
64.1
Neutral
MACD (12,26,9)
3.55
Hist 1.32
ATR (14)
5.56
2.10% of price
Realised vol 30D
25.1%
Annualised
Bollinger upper
267.94
20, 2σ
Bollinger lower
238.65
20, 2σ
50 / 200 cross
Golden
247.99 vs 226.56
Trend bias
Above 200
+16.95%
Risk profile
Beta vs SPY
-0.07
Less volatile than market
Correlation to SPY
-0.04
Largely independent
Realised vol 30D
25.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-19.2%
Peak to trough
Max drawdown 5Y
-24.3%
Peak to trough
ATR 14
5.56
2.10% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Lilly's Multiple Assumes Less Growth Than You Think
Trefis · 14h ago
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market
Trefis · 15h ago
AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026
Simply Wall St. · 17h ago
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
PR Newswire · 21h ago
3 Unpopular Stocks That Deserve Some Love
StockStory · 22h ago
Merck Stock Ran On A Checklist Published In Advance
Trefis · 2d ago
Pfizer Stock Is A Race Between New Drugs And Old Patents
Trefis · 2d ago
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead
24/7 Wall St. · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.